Brilinta "Complete Response" Letter Suggests FDA Unswayed On U.S. Efficacy
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency asks AstraZeneca for additional analyses of data from the 18,000-patient PLATO study, in which no benefit of ticagrelor over clopidogrel was seen in U.S. acute coronary syndrome patients.